All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior PD-1 or PD-L1 therapy (PD-X refractory)
Encouraging interim Disease Control Rate (DCR) of 36.1% (13/36) and 26% progression free at 6 months
73.7% of evaluable patients (14/19) had tumour shrinkage or tumour growth deceleration compared to pre-study situation
Encouraging preliminary Overall Survival (OS) at the 6-month landmark, with a 73% survival rate
5.6% of patients (2/36) had confirmed and durable partial responses, with both patients continuing in the trial for over 9 months and 23 months, well beyond expectations
Efti continues to be safe and well tolerated
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.